A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 38/19 (2006.01) A61K 45/06 (2006.01) C07H 21/00 (2006.01) C12N 15/00 (2006.01) C12N 15/09 (2006.01) C12N 15/63 (2006.01) C12N 15/67 (2006.01) C12N 15/85 (2006.01) C12N 15/861 (2006.01)
Patent
CA 2442971
The present invention provides for improved therapeutic regimens for treating benign hyperproliferative diseases and cancers. The Egr-1 promoter, long known to be radiation-responsive, has now been shown to be inducible for DNA damaging chemical agents, many of which themselves are used in therapies. Thus, the present invention provides for the advantages combination of a DNA damaging chemical and an expression vector containing a therapeutic gene driven by the Egr-1 promoter.
L'invention concerne des schémas thérapeutiques améliorés destinés au traitement des maladies hyperprolifératives et du cancer. Le promoteur Egr-1, connu depuis longtemps pour être sensible à l'irradiation, s'avère inductible pour les agents chimiques qui endommagent l'ADN et dont plusieurs sont eux-mêmes utilisés en thérapie. Cette invention combine avantageusement un produit chimique qui endommage l'ADN et un vecteur d'expression qui contient un gène thérapeutique mû par le promoteur Egr-1.
Gupta Vinay
Kufe Donald W.
Mauceri Helena
Park James
Posner Mitchell
Dana-Farber Cancer Institute
Fetherstonhaugh & Co.
University Of Chicago
LandOfFree
Chemotherapeutic induction of egr-1 promoter activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemotherapeutic induction of egr-1 promoter activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemotherapeutic induction of egr-1 promoter activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1478200